1.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 120
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLBH589B2201, NCT00425555
|
|
2.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLBH589B2212, NCT00490776
|
|
3.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLBH589C2204, NCT00567879
|
|
4.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: 08-0172, NCT00691938
|
|
5.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MCC-15461, IND 102483, LBH589, NCT00738751
|
|
6.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: Over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLBH589C2114, EudraCT 2007-004788-23, NCT00788931
|
|
7.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 65 and over
Sponsor: Other
Protocol IDs: PANOBIDARA, NCT00840346
|
|
8.
|
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-342, CLBH589BUS42T, NCT00859222
|
|
9.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: NYU 08-479, NCT00878436
|
|
10.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SCRI GU 49, IND 79,340, NCT00550277
|
|
11.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SCRI MDS 07, 79,698, NCT00594230
|
|
12.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLBH589C2208, NCT00667862
|
|
13.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CLBH589BUS19T, CRC GOLP CNOV 0823, NCT00690677
|
|
14.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CHNMC-07174, 07174, NOVARTIS-CHNMC-07174, NCT00723203
|
|
15.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLBH589E2214, NCT00742027
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: TRIO 017, NCT00777049
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: TRIO 016, NCT00777335
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: LIBTC-2008-1, NCT00848523
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLBH589B2213, EUdraCT 2008-002983-32, NCT00880269
|
|
20.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLBH589B2207, NCT00532389
|
|
21.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLBH589B2206, NCT00532675
|
|
22.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CLBH589B2109, NCT00535951
|
|
23.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SCRI REFMAL 120, IND 79,355, NCT00550199
|
|
24.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SCRI REFMAL 121, NCT00556088
|
|
25.
|
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SCRI REFMAL 119, NCT00632489
|
